A prospective cohort study of mineral metabolism after kidney transplantation

Transplantation

Volumn 100, Issue 1, 2016, Pages 184-193

  Wolf, Myles ^a   Weir, Matthew R ^b   Kopyt, Nelson ^c   Mannon, Roslyn B ^d   Visger, Jon Von ^e   Deng, Hongjie ^f   Yue, Susan ^f   Vincenti, Flavio ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c LEHIGH VALLEY HOSPITAL   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f AMGEN INC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; STEROL DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D STEROL DERIVATIVE; BIOLOGICAL MARKER; CALCIUM; FIBROBLAST GROWTH FACTOR; PHOSPHATE; PTH PROTEIN, HUMAN;

ADULT; COHORT ANALYSIS; CONFERENCE PAPER; DISEASE COURSE; FEMALE; GRAFT RECIPIENT; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARATHYROIDECTOMY; PERSISTENT HYPERPARATHYROIDISM; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; UNITED STATES; AGED; BLOOD; CLINICAL TRIAL; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BIOMARKERS; CALCIUM; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PREVALENCE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84952360920     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000823     Document Type: Conference Paper

References (55)

1. US Renal Data System (USRDS). USRDS Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States Vol 7.2. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2013.
2. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74:276-288.
3. CunninghamJ, Locatelli F, RodriguezM. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913-921.
4. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-4408.
5. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO (4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12: 2131-2138.
6. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272-2279.
7. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67:760-771.
8. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432-2439.
9. Alam MU, Kirton JP, Wilkinson FL, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res. 2009;81:260-268.
10. Floege J, KettelerM. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant. 2004;19(Suppl 5):V59-V66.
11. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998;11:239-245.
12. Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol. 2011;22:956-966.
13. Apostolou T, Damianou L, Kotsiev V, et al. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clin Nephrol. 2006;65: 374-377.
14. Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a singlecentre study. Nephrol Dial Transplant. 2004;19:1281-1287.
15. Evenepoel P, Kuypers D, Maes B, et al. Persistent hyperparathyroidism after kidney transplantation requiring parathyroidectomy. Acta Otorhinolaryngol Belg. 2001;55:177-186.
16. Evenepoel P, Lerut E, Naesens M, et al. Localization, etiology and impact of calcium phosphate deposits in renal allografts. Am J Transplant. 2009;9:2470-2478.
17. Hamdy NA. Calcium and bone metabolism pre-And post-kidney transplantation. Endocrinol Metab Clin North Am. 2007;36:923-935 viii.
18. Heaf J, Tvedegaard E, Kanstrup IL, et al. Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant. 2000;14:457-463.
19. Bhan I, Shah A, Holmes J, et al. Post-Transplant hypophosphatemia: tertiary hyper-phosphatoninism? Kidney Int. 2006;70:1486-1494.
20. Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol. 2013;33:191-203.
21. Benavente D, Chue CD, Moore J, et al. Serum phosphate measured at 6 and 12 months after successful kidney transplant is independently associated with subsequent graft loss. Exp Clin Transplant. 2012;10: 119-124.
22. Connolly GM, Cunningham R, McNamee PT, et al. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation. 2009;87:1040-1044.
23. Mazzaferro S, Pasquali M, Taggi F, et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol. 2009;4:685-690.
24. Meneghini M, Regalia A, Alfieri C, et al. Calcium and osteoprotegerin levels predict the progression of the abdominal aortic calcifications after kidney transplantation. Transplantation. 2013;96:42-48.
25. Perrin P, Caillard S, Javier RM, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13:2653-2663.
26. Al-Gabri S, Zadrazil J, Krejc K, et al. Changes in bone mineral density and selected metabolic parameters over 24 months following renal transplantation. Transplant Proc. 2005;37:1014-1019.
27. Sprague SM, Belozeroff V, Danese MD, et al. Abnormal bone and mineral metabolism in kidney transplant patients-A review. Am J Nephrol. 2008;28:246-253.
28. Tuchman S, Kalkwarf HJ, Zemel BS, et al. Vitamin D deficiency and parathyroid hormone levels following renal transplantation in children. Pediatr Nephrol. 2010;25:2509-2516.
29. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
30. Barros X, Torregrosa JV, Martnez de Osaba MJ, et al. Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients. Transplantation. 2012;94:830-836.
31. Reinhardt W, Bartelworth H, Jockenhvel F, et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant. 1998;13:436-442.
32. Snchez Fructuoso AI, Maestro ML, Calvo N, et al. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation. Transplant Proc. 2012;44: 2551-2554.
33. Sirilak S, Chatsrisak K, Ingsathit A, et al. Renal phosphate loss in longterm kidney transplantation. Clin J Am Soc Nephrol. 2012;7:323-331.
34. Evenepoel P, Meijers BK, de Jonge H, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008;3: 1829-1836.
35. Economidou D, Dovas S, Papagianni A, et al. FGF-23 levels before and after renal transplantation. J Transplant. 2009;2009:379082.
36. Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006; 104:23-32.
37. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82:737-747.
38. Yilmaz MI, Sonmez A, Saglam M, et al. Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after renal transplantation. Am J Nephrol. 2013;37:126-134.
39. Lavi-Moshayoff V,Wasserman G, Meir T, et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299:F882-F889.
40. Lpez I, Rodrguez-Ortiz ME, Almadn Y, et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 2011;80:475-482.
41. Rhee Y, Bivi N, Farrow E, et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone. 2011;49:636-643.
42. Wesseling-Perry K, HarkinsGC,Wang HJ, et al. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin EndocrinolMetab. 2010;95:2772-2780.
43. Ball AM, Gillen DL, Sherrard D, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002;288:3014-3018.
44. Sukumaran Nair S, Lenihan CR, Montez-Rath ME, et al. Temporal trends in the incidence, treatment and outcomes of hip fracture after first kidney transplantation in the United States. Am J Transplant. 2014;14:943-951.
45. Bosworth CR, Levin G, Robinson-Cohen C, et al. The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int. 2012;82:693-700.
46. Alshayeb H, Showkat A, Wall BM, et al. Activation of FGF-23 mediated vitamin D degradative pathways by cholecalciferol. J Clin Endocrinol Metab. 2014;99:E1830-E1837.
47. Bleskestad IH, Bergrem H, Leivestad T, et al. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014;28:479-486.
48. Molnar MZ, Kovesdy CP, Mucsi I, et al. Association of pre-kidney transplant markers of mineral and bone disorder with post-Transplant outcomes. Clin J Am Soc Nephrol. 2012;7:1859-1871.
49. Cohen JB, Gordon CE, Balk EM, et al. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-Analysis. Transplantation. 2012;94:1041-1048.
50. CourbebaisseM, Diet C, TimsitMO, et al. Effects of cinacalcet in renal transplant patients with hyperparathyroidism. Am J Nephrol. 2012;35:341-348.
51. Aalten J, Wetzels JF, Hoitsma AJ. Continuation of cinacalcet immediately after renal transplantation: a prospective cohort study. Clin Nephrol. 2010;74:433-439.
52. Paschoalin RP, Torregrosa JV, Barros X, et al. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-Term follow-up and effect of withdrawal. Transplant Proc. 2012;44:2376-2378.
53. Torregrosa JV, Bergua C, Martinez de Osaba MJ, et al. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis. Transplant Proc. 2009;41:2396-2398.
54. Torregrosa JV, Morales E, Daz JM, et al. Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: A multicentre, retrospective, 3-year study. Nephrology (Carlton). 2014;19:84-93.
55. Evenepoel P, Cooper K, Holdaas H, et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant. 2014;14:2545-2555.